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Abstract
Alternative splicing (ASfootnote_1) of RNA is a key mechanism for diversification of the
eukaryotic proteome. In this process, different mRNA transcripts can be produced through altered
excision/inclusion of exons during processing of the pre-mRNA molecule. Since its discovery, AS
has been shown to play roles in protein structure, function, and localization. Dysregulation of this
process can result in disease phenotypes. Moreover, AS pathways are promising therapeutic
targets for a number of diseases. Integral membrane proteins (MPs) represent a class of proteins
that may be particularly amenable to regulation by alternative splicing due to the distinctive
topological restraints associated with their folding, structure, trafficking, and function. Here, we
review the impact of AS on MP form and function, and the roles of AS in MP-related disorders
such as Alzheimer’s disease.
Introduction to Splicing of Pre-mRNA
In 1941, Beadle and Tatum provided data that led to the “one gene, one protein” paradigm
(1). This paradigm persisted until researchers began to explore the human genome in depth,
at which point it was discovered that the number of protein-encoding genes is much lower
than originally predicted—leading to the “one gene, many proteins” hypothesis. Seminal
work with adenovirus (2, 3) first led to the notion that multiple transcripts can arise from the
same precursor RNA molecule. In 1978 a new mechanism, now known as alternative
splicing (AS), was proposed (4) to generate proteomic diversity from a single gene in
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eukaryotes, and experimental confirmation quickly followed (5). During the maturation of
mRNA in eukaryotes, RNA is spliced to remove regions of pre-mRNA referred to as introns
(6–11). The remaining segments, referred to as exons, are linked and can act in both protein-
coding and non-coding functions. Differential splicing, in which different exons or regions
of exons are included or excluded in construction of the final coding mRNA, provides the
basis for allowing a relatively small number of genes to encode for a large and diverse
number of proteins. In addition to providing diversity to the proteome, AS may also regulate
translation through the introduction of premature stop codons (via several possible
mechanisms) that promote nonsense-mediated decay (NMD) of the alternatively spliced
transcript (see (12–16)).
While the removal of introns is common to all eukaryotic life forms, the percentage of genes
that undergo splicing varies by species. Generally, the abundance of AS events is
proportional to organismal complexity, with AS being most prevalent in more complex
organisms such as vertebrates (17). In higher eukaryotes, AS is ubiquitous, with at least 90%
of human gene transcripts subjected to this process (18). Additionally, typical exon length
decreases with increasing organism complexity (19), with 80% of human exons being less
than 200 base pairs in length (20), which means that many exons encode only short
segments of the protein product. In addition to differences among species, there is also
diversity of AS within an organism. The number of potential AS products varies by gene
and the expressed isoform(s) of any given protein can vary by cell type and even state of
differentiation (21).
There are several types of AS that can take place within a given transcript, including exon
skipping (ES), alternative donor sites (AD), alternative acceptor sites (AA), intron retention
(IR), and the rare complex event known as mutually exclusive (ME) exon splicing. Other
rare complex events, such as the skipping of multiple exons in a row, also occur (22). In a
recent analysis of the human AS landscape, it was demonstrated that by far the most
common AS events are the four “simple” modes of AS: ES, AD, AA, and IR, respectively,
with ES accounting for approximately 45% of AS events (23) (see Figure 1). However,
more complex types of AS, such as the skipping of two exons in a row (ca. 6–12% of total
AS events), skipping of three exons in a row (ca. 2–3% of total AS events, and ME (ca. 3–
5% of total AS events), do account for roughly 30% of total AS outcomes, making complex
modes of AS important contributors to genomic diversity. ME exons often encode the same
structural domain of the protein with slight variations (24), giving this mode of AS
important roles in tuning protein structure and functions.
Splicing occurs by two consecutive transesterification reactions (25) that are catalyzed by
the spliceosome, a ~3 MDa macromolecular machine composed of four of snRNAs (small
nuclear RNAs) and proteins (see Figure 2). In a popular model based on in vitro studies, this
apparatus is postulated to assemble in a step-wise and dynamic fashion (26, 27). In the
process of spliceosome assembly, several intermediary complexes form (see Figure 2, (6–
11) and (28)). The spliceosome recognizes three primary splicing signals: the 5' and 3' splice
sites and the branch site. In the first transesterification reaction, the 2'-OH of a conserved
adenosine nucleotide within the intervening intron region performs a nucleophilic attack,
resulting in the release of the 5' exon containing a free 3'-OH group and the formation of the
lariat intermediate structure. In the second step, the 3'-OH of the 5' exon serves as the
nucleophile at the 3' splice site, producing the ligated exons and releasing the 2'–5' branched
lariat intron. Spliceosome assembly begins with the recognition of the 5' splice site and
branch point sequences of the pre-mRNA by the U1 snRNP and the U2 snRNP respectively.
After binding of the U4/U6.U5 tri-snRNP, the U4/U6 snRNA duplex is replaced by a U2/U6
snRNA duplex. Furthermore, the U1 snRNA base pairing at the 5' splice site is disrupted
and exchanged for base pairing between the 5' splice site and the U6 snRNA. The
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subsequent addition of another complex, the NTC (Nineteen complex) and the release of the
U1 and U4 snRNPs marks the transition from an inactive to an active spliceosome
composed of the NTC, and the U5 and U2/U6 snRNPs. 5' splice site cleavage and lariat
formation, followed by 3' splice site cleavage and exon ligation, occurs within the activated
spliceosome. After completion of the second transesterification step and ligation of the two
exons, the post-spliceosomal complex is dismantled and the lariat intron is released (see
Figure 2). In each step of spliceosome assembly, catalysis, and disassembly, there are a
number of RNA helicases and other enzymes that are needed to aid and regulate the many
RNA:RNA, RNA:protein, and protein:protein interactions (9).
Most introns contain conventional consensus sequences that delineate the primary splice
sites (8–10, 29). The 5' splice site typically begins with a conserved GU, which is flanked by
three residues on the exon side and seven residues on the intron side that are generally
similar among 5' splice sites. The 3' splice site usually follows the trinucleotide CAG or
UAG (or, more rarely, AAG). The first nucleotide of the adjacent exon is also partially
conserved. In addition to these consensus sequences, a tract of pyrimidine-rich bases
upstream of the 3' splice site also contributes to recognition by the spliceosome. The final
primary determinant of splice site recognition is the branch site consensus sequence,
typically UACUAAC, where the final A serves as the nucleophilic branch site nucleotide
and forms the lariat structure depicted in Figure 2. While this sequence is the most preferred
by the splicing machinery, variation does occur around the branch site in certain cases.
There is also another, less common, class of introns present in higher eukaryotes that utilizes
both distinct consensus sequences (|ATATCCTT at the 5' splice site, CCTTRACCY at the
branch site, and YAC| at the 3' splice site, where the vertical line indicates the actual site of
the splicing event) and distinct spliceosomal components (the U11, U12, U4atac, and U6atac
snRNPs, which are analogous to the U1, U2, U4, and U6 snRNPs, respectively). This minor
spliceosome form proceeds through a step-wise reaction pathway identical to that depicted
in Figure 2 and accounts for less than 1% of introns in human cells.
In addition to the primary determinants discussed above, there are other sequence signals
outside of the conventional splice sites that regulate splicing. For instance, splicing
enhancers and suppressors either promote or reduce the incidence of splicing at a particular
site (30, 31). The relative strengths of multiple splice sites in the same sequence vicinity can
also play roles in determining which site the spliceosome recognizes. RNA secondary
structure also often appears to play a role in splice site selection (32–34). In another
surprising mechanism, histone modifications present on the nucleosomes binding to exonic
regions of DNA have also been directly linked to splicing outcomes (35). Together, these
extra determinants outside the canonical splice site sequences provide additional ways for
the spliceosome to distinguish the “correct” splice site from similar, but inappropriate, sites
found elsewhere in the gene. Although these extra determinants complicate the “splicing
code”, making it difficult to untangle which transcripts form from various genes, they serve
as an important mechanism for “fine-tuning” splice site selection, providing the flexibility to
precisely regulate which sequences are spliced or retained
With the currently available understanding about splice site consensus sequences and other
signals that affect splicing, one might expect there to be robust computational approaches
that would accurately predict exon/intron boundaries. Indeed this is the goal of several
online splice site locator and gene structure prediction tools (36–39); however, the additional
signals that regulate splicing discussed above often make these predictions complicated and
occasionally inaccurate. A recent study (40) has taken further steps to incorporate regulatory
information in the prediction algorithms allowing the prediction of tissue-specific alternative
splicing. That study utilized information on experimentally-determined splice variants from
four types of major tissue in mice, as well as information regarding the potential “splicing
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code”. This code includes sequences: (1) shown to recruit regulatory proteins, (2) that are
enriched around splice sites, (3) containing RNA secondary structure, and (4) that contain
spatial relationships between exons, introns, and other sequence motifs (40, 41). As a result
of that study, an online tool (Website for Alternative Splicing Prediction, or WASP) was
developed for de novo gene structure prediction as well as de novo prediction of the splice
variants present in four major tissues (http://genes.toronto.edu/wasp/). Hopefully, the
continued updates of WASP to reflect our improving and growing knowledge of the splicing
code will eventually lead to an accurate tool for predicting gene structure and cell- and
tissue-specific profiles of transcript variant expression. Finally, it should be noted that in
addition to the computational algorithms for de novo prediction of gene structure and
alternative splicing events, there are several databases that compile known splice variants
and tissue expression profiles of genes (36), including a database (TMSPLICE) that
specifically documents alternative splicing events in MPs within the mouse genome (42).
Alternative splicing provides an important mechanism for higher eukaryotes to both increase
genetic diversity and regulate protein activity. Splicing variation affects the structure,
function, and expression levels of protein products. Exploring alterations in physiology
caused by AS is important to better understand the ramifications of misregulated AS and,
ultimately, the role of AS in disease processes (43–46). This review will focus on how AS
impacts membrane proteins (MP).
RNA Splicing and Membrane Proteins (MP)
MPs play key roles in numerous cellular functions including cell signaling, transport, energy
transduction, as well as in the organization and stabilization of cellular structure. MPs differ
from soluble proteins in terms of native environment, folding topology, and organization of
domains and subunits. It is well established that RNA splicing can have a wide range of
effects on soluble protein expression, localization, folding, structure, and function (47).
There are also many examples of the role of AS in regulating MPs. However, there is
currently no published survey of how AS impacts membrane proteins in ways that reflect the
unique properties of this class of proteins. Here, we present a number of examples to
illustrate how RNA splicing can alter MP expression, distribution, folding, topology,
structure, and function. Care has been taken to highlight examples that represent a cross-
function of MP types, including channels, transporters, receptors, structural proteins, and
enzymes. The wide range of effects exerted by AS on MPs suggest that AS acts as a little-
recognized global regulator of MP structure and function in higher organisms and thus has
important implications for human disease.
AS Can Alter MP Topology or Produce Soluble Proteins
The number and arrangement of transmembrane (TM) segments in a MP defines the
orientation of a protein and is often closely integrated with function and stability.
Alternative or aberrant splicing can disrupt TM segments when splice sites are found within
a TM-encoding region of the transcript. Likewise, it is possible that removal of an entire TM
segment via splicing can significantly alter the topology of a MP or even eliminate
membrane anchoring altogether. In this section, we review placement of splice junction
locations within MP gene structure and examine examples where splicing significantly alters
MP topology. We also briefly discuss the impact of these AS events on MP function.
Intron Junctions Tend Not to be Localized Within TM-Encoding Segments—
The aberrant introduction of splice site junctions within TM segments would likely lead to
serious disruption of the encoded membrane protein structure. Indeed, computational studies
assessing the likelihood of an intronic division within a TM region have found that that the
probability of a TM not being divided by an intron was slightly higher than the expected
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probability for a random 22-mer amino acid sequence (42). This difference was most
pronounced in single-pass MPs, where TM regions were encoded on single exons 84.6% of
the time, in comparison with the random sequence expectation of 58.5%. Thus, there seems
to be evolutionary pressure for MPs, especially single pass MPs, to keep introns out of
regions coding TMs within pre-mRNA.
AS Can Produce MPs with Altered Topology—Rh blood group antigens are
important in blood-typing for blood transfusion and organ transplantation. These antigens
are typically predicted to have 12 TM segments (48). The RhCcEe proteins represent an
example of MPs whose topologies are altered due to AS (49). The characterization of Rh
cDNA clones led to the conclusion that at least four different transcripts are produced from
the RhCcEe gene by AS (Figure 3). Exon removal in one of the isoforms (RhVIII) results in
the removal of residues 163–313, which form five TM segments. As a result, three of the
helices are predicted to cross the membrane in reverse orientation relative to the original
full-length transcript. Inversion of TM segment topology also occurs in isoform RhVI,
which, as a result of exon removal, is missing residues 163–267, which form three TM
segments. The reversal alters the residues that are surface-exposed and may alter
antigenicity (see Figure 3A). Additionally, RhVI has another deletion (corresponding to
residues 359–384) due to exon removal. This deletion causes a frameshift and results in a
different C-terminal sequence with a premature stop codon. The Rh4 isoform is missing
amino acid residues 314 to 358 as a result of exon removal; this exon deletion event induces
a frameshift resulting in a different C-terminal sequence and a premature stop codon at the
same location as in RhVI. Interestingly, the new C-terminal sequence generated by the
frameshift in RhVI and Rh4 encodes the same 14 amino acids, indicating that this sequence
is likely important, although its function is not yet known (see Figure 3).
Another example of altered TM topology is found in the V2 vasopressin receptor, a G-
protein coupled receptor (GPCR). Its two isoforms, V2a and V2b, were found to have
different topological states and different levels of stability (50) (Figure 3B). V2a is a stably
expressed seven-TM segment (7-TM) protein found at the plasma membrane. Conversely,
V2b differs in sequence from V2a in the C-terminal region after the sixth TM segment. This
altered C-terminal tail results from the use of an alternate 3' splice site 76 base pairs
downstream of the canonical 3' splice site, which results in a frameshift. The V2b protein
isoform was experimentally shown to significantly populate two different topologies: a 7-
TM topology similar to canonical GPCRs with the C-terminus located intracellularly, and a
6-TM topology with the C-terminus oriented to the extracellular matrix (Figure 3B). The
V2b receptor also differs in that it is localized to the ER and Golgi apparatus rather than
trafficking to the plasma membrane. Retention of the protein in the ER and Golgi could be
due either to the splicing-based deletion of C-terminal forwards-trafficking motifs or may
reflect sequestration of the truncated protein by MP folding quality control.
A third protein whose TM topology is affected by alternative splicing is the glycine receptor
(51), which assembles into heteropentameric (α2β3) ion-conducting pores and acts to
mediate neurotransmissions in the central nervous system. It was found that the β subunit of
this receptor was alternatively spliced to remove exon 7 (βΔ7). The long isoform of the β
subunit including exon 7 possesses a predicted four-TM topology while the βΔ7 variant
possesses a predicted two-TM segment topology due to the removal of TM segment 1, the
first intracellular loop and a portion of TM segment 2 (see Figure 3C). Interestingly, the
extracellular domain is kept intact, the protein is stably expressed in the cerebral cortex and
can hetero-oligomerize with the glycine receptor α-subunits or with the glycine receptor-
anchoring protein gephyrin. Because the TM segment 2 (which is shortened in βΔ7, where
it is instead predicted to form the tenth beta strand in the large extracellular domain) is part
of the ion conduction pathway, the functional properties of glycine receptors containing βΔ7
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may be different. Indeed, experiments showed that the α1βΔ7 complexes did not have
resistance to the channel blocking agent picrotoxin while α1β complexes display this
property (51), suggesting that the pore is formed only by the α-subunits.
AS Can Alter the Signal Peptide—Signal peptides are important for membrane
targeting and determination of protein subcellular localization and are often altered as a
result of AS. In a computational analysis of the mouse transcriptome, 40% of transcriptional
units (sets of transcripts derived from the same gene) were shown to have signal peptide
variation, with the majority of transcript variation being the consequence of AS (52). These
alterations are important for the targeting soluble proteins to various subcellular
compartments (lumen of endoplasmic reticulum vs. cytosol, for example). Signal peptides
also play an important role for targeting and integration of proteins into membrane, where
they help determine membrane protein topology. The same study investigated a high-
confidence set of 782 transcriptional units, where the presence of alternative transcription
initiation start and termination sites in transcripts were independently confirmed, with
variations in membrane organization. While this set most likely excludes most examples of
AS based on the selection criteria, it is important to note that the AS may accomplish a
similar task in cells based on alternative initial exons. In the same set of transcripts, there
were 41 instances of signal peptide removal that resulted in a switch from Type I (C-
terminal cytosolic) TM topology to Type II (N-terminal) TM topology in single-pass TM
proteins. It is likely that use of alternative initial exons, which make up 58% of the
mechanisms of variation among the set of transcriptional units with signal peptide variation
investigated in this study, could result in a similar total inversion of topology. It seems
feasible that AS could also result in complete inversion of topology of multi-span membrane
proteins. There are MPs of this class that are known to populate opposite topologies (53),
although splicing has not so far been established as the driving mechanism.
Signal peptide removal by AS has been documented in the parathyroid hormone (PTH)/
PTH-related peptide (PTHrP) receptor (54). The gene for this GPCR can be transcribed from
two different transcription start sites. Use of a novel promoter in kidney results in the
generation of three alternatively spliced transcripts (type I-type III), of which the signal
peptide is replaced with a hydrophilic sequence in the type III splice variant. This splice
variant, which was shown to retain reactivity, was expressed only minimally on the cell
surface, with the majority being localized to intracellular compartments, likely as a result of
replacement of the signal peptide. The type III receptor could be reactive to an intracellular
form of PTHrP or may simply represent the outcome of a downregulatory mechanism.
AS Can Result in Production of Soluble Proteins from MP-Encoding Genes—
In addition to altered TM topology, alternative splicing can eliminate TM domains from
transcripts that would otherwise encode MPs. This results in soluble protein isoforms that
may have vastly different roles in (or out) of the cell. A survey (55) of a portion of the
human MP transcriptome revealed that nearly 40% of the 464 surveyed alternatively spliced
single-pass MP genes have isoforms that completely lack a TM domain (Figure 4A). For
example, the alternatively spliced soluble isoform of the syndecan-4 receptor (SCD-4) is
very similar to the ectodomain of the canonical isoform. Syndecan receptors normally
function as co-receptors by concentrating and presenting a variety of ligands (e.g.
extracellular matrix proteins, growth factors, cytokines, and cell adhesion molecules) to
other cell surface receptors, or they act to internalize ligand, sequestering them away from
other receptors, thereby modulating signaling. The ectodomain of SCD-4 can be
proteolytically cleaved, an event that is regulated by multiple signaling pathways, and this
solubilized domain can still bind ligand, affecting signaling by competing with the
membrane-bound SCD-4 counterpart (56). It is possible that the AS soluble isoform may
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play a similar ligand-sequestration role as that played by the ectodomain generated by
proteolytic cleavage.
Another example of production of a soluble isoform from a MP transcript is cadherin-7, a
cell-adhesion TM glycoprotein. In developing chickens, it was found that a soluble form of
cadherin-7 was expressed (57) and that this isoform can interact with the corresponding
domain in the TM variant of this same protein, resulting in inhibition of cell-cell adhesion
by interfering with homomeric interactions of the TM form.
AS Can Alter MP Function
Channels—Ions cannot cross the hydrophobic lipid bilayer via diffusion. Cells therefore
express numerous types of channels, both to regulate cytosolic ion content and, in the case
of specialized cells such as neurons and muscle cells, for signaling purposes. Ion channel
activity can be regulated by AS. For example, transient receptor potential (TRP) potassium
channels are heavily regulated by AS (58). The functional impact can range from altered
conductance to changes in selectivity or activation. More drastic changes include the
generation of dominant negative isoforms that prevent native channel function through
heteromultimerization with the canonical isoforms. Consider the cold/menthol sensitive
TRPM8 channel. Bidaux et al (59) have described the activity of two newly discovered short
isoforms of TRPM8 (dubbed short TRPM8α and short TRPM8β). These two short isoforms
contain only the cytosolic N-terminal domain and are thus are not capable of forming
functional channels, but bind to and regulate canonical long-form TRPM8 channel tetramers
(Figure 4B). Specifically, these variants stabilize the closed form of the channel, reducing
channel activity and sensitivity to cold.
The TRPM3 channel is alternatively spliced to produce different sequences within the
presumed pore domain, generating different cation selectivities. For instance, TRPM3α1
and TRPM3α2 are both outwardly rectifying cation channel isoforms, meaning they allow
higher current flux out of the cell than in, whereas other TRPM3 variants are inwardly
rectifying. TRPM3α2 is highly permeable to divalent cations while TRPM3α1 favors
monovalent conductance. Additionally, monovalent cations block currents through
TRPM3α2 but not TRPM3α1. These TRPM3 variants clearly demonstrate a role for AS in
regulating channel ion permeability, selectivity, and regulation (60).
Transporters—Transporters facilitate the passage or flip-flop of solutes across the
membrane, often in an energy-consuming manner against the TM concentration gradient
(active transport). Transporter activity is typically tightly regulated, with AS being one
mechanism of regulation.
An important family of regulated transporters are the P-type ATPases. This family includes
the plasma membrane calcium pump, which is present in all eukaryotic cells and helps to
maintain appropriate Ca2+ levels within the cytosol by moving calcium ions from the
cytosol to the extracellular matrix. The calcium pump is alternatively spliced such that its
calmodulin-binding regulatory domain is altered to reduce its net positive charge, resulting
in a lower calmodulin affinity (61). Reduced affinity of the ATPase for calmodulin results in
reduced transporter affinity for cytosolic Ca2+ ions.
Another example is the glutamate transporter family. After release of neurotransmitter into
the synaptic cleft, transporters are responsible for transmitter reuptake by the cell and
regulation of the volume of these vital molecules at the synapse. Levels of glutamate, the
major excitatory neurotransmitter in the brain, are regulated by glutamate transporters, the
most prominent of which is GLT1 (EEAT2 in humans). The three alternatively spliced
isoforms of this protein (GLT1a, GLT1b, GLT1c) differ in their C-termini (62), with both
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GLT1b and GLT1c containing a PDZ-recognition motif. GLT1a lacks this sequence (Figure
4C). Inclusion of a PDZ-binding sequence likely has functional consequences for the
different GLT1 isoforms, since they may then recruit PDZ domain-containing proteins that
modulate transporter function, trafficking, or associated signaling. GLT1a and GLT1b have
similar expression profiles, and are primarily expressed in the brain, while GLT1c is
expressed in the retina.
Receptors—G protein-coupled receptors (GPCRs) are an essential subset of MP, the target
of almost 40% of the drugs on the market today (63) and represent an interesting example in
terms of AS. Although many GPCR-encoding genes do not contain introns, some GPCR
genes do (64–66). Besides the V2R and PTHrP receptors discussed earlier, classic examples
include the D2 dopamine receptor and the rat type I pituitary adenylate cyclase-activating
peptide receptor (PAC1 receptor). The D2 receptor is present in one of two isoforms in the
central nervous system (CNS): short (D2S) or long (D2L). The D2S receptor lacks 29 residues
within the third intracellular loop, likely resulting in different signaling properties due to the
role of the intracellular loops in interaction with its cognate G-protein (64). The PAC1
receptor is expressed in five different isoforms, all with variations in the third intracellular
loop resulting in different signaling properties. The alternative forms of this loop
differentially regulate activation of the downstream effectors adenylate cyclase and
phospholipase C (64), again, most likely by altering interactions and specificity between the
receptor and heterotrimeric G proteins.
In the case of the cannabinoid receptor hCB1, two splice variants have been identified
(hCB1a and hCB1b) in addition to the canonical receptor. These variants have altered amino
termini; hCB1a has an altered N-terminal sequence and hCB1b is missing the first 33 N-
terminal amino acid residues. In both cases AS occurs through use of different splice site
donor/acceptor sites. hCB1a and hCB1b display altered pharmacological properties in
relation to the canonical hCB1 receptor (Figure 4E). Their affinity for the native ligand
anandamide is dramatically reduced and their affinity for 2-arachidonoylglycerol is
somewhat decreased. Additionally, it was found that instead of acting as an agonist, as it
does in the hCB1, 2-arachidonoylglycerol functioned as an inverse agonist when interacting
with hCB1a and hCB1b (67). Because the N-termini are not in the ligand-binding site, this
example points to a function of AS in allosteric regulation of receptors.
Enzymes—TM enzymes are also affected by AS. Carbonic anhydrase XII (CA XII) is an
enzyme whose alternative splicing is associated with cancer (68). There are two alternative
transcripts of CA XII, the longer of which encodes 11 additional amino acid residues
immediately preceding the predicted TM domain. Both transcripts are found in healthy
tissue, but the longer isoform normally dominates. However, in astrocytomas expression of
the shorter isoform is greatly increased and the longer isoform was rarely detected. Why the
shorter isoform is more prevalent in cancer cells is not well understood; although, it is likely
that the shorter isoform of CA XII may have difficulty in forming its normal quaternary
structure. This is because a portion (GXXX) of the GXXXG motif, important for
homodimerization of the enzyme, is missing due to alternative splicing (Figure 4D). Thus
quaternary structure disruption likely contributes to catalytic dysfunction. For additional
examples of enzymes affected by AS, see the Alzheimer’s disease section.
Structural Proteins—The proteolipid protein (PLP) is the most abundant protein of
central nervous system (CNS) myelin and is thought to maintain structural integrity of
myelin and support myelin compaction, although it may have additional roles in signaling
(69). PLP is a tetraspan MP with an intracellular “principal loop” connecting TM helices II
and III. DM-20 is a splice variant of PLP and lacks a large portion (34 amino acids) of the
principal loop (70), including two palmitoylation sites (71) (Figure 4F). It is likely that this
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region allows for differential regulation of the functions of PLP and DM-20, altering their
trafficking, structure, and/or signaling functions. It is interesting to note that AS-based
elimination of two palmitoylation sites may also reduce the propensity of DM-20 to interact
with cholesterol-rich membrane domains often referred to as “lipid rafts” or other
specialized membrane domains in myelin membranes.
Regulation of Protein-Protein Interactions—Differences in alternatively spliced
isoforms can impact the ability of the protein product to interact with partners. As discussed
above, the GLT1 transporter isoforms differ in their possession of a PDZ-binding motif, a
motif likely used to bind protein partners containing PDZ-binding domains. Another
example is the N-methyl-D-asparate (NMDA) receptor. Yotiao, an A-kinase anchoring
protein, scaffolds to the NR1A splice variant of the NR1 subunit of the NMDA receptor but
not to the NR1C splice variant (72). This interaction is modulated by either the presence or
absence of a subdomain encoded by an alternatively spliced C1 exon cassette that is
included in NR1A but not the NR1C splice isoform. Additional research suggests that
Yotiao may mediate a ternary complex between itself, the NMDA receptor and cAMP-
dependent protein kinase II. This interaction is postulated to provide a mechanism for cAMP
to modulate NMDA-receptor signaling (73). Similarly, calmodulin interacts avidly with the
receptor through binding of NR1A to the region encoded by the very same C1 exon cassette,
thereby inhibiting NMDA receptor function (74, 75).
Tissue-Specific AS
Through tissue-specific isoform expression, AS can alter the function of the protein product
of a gene to better suit the requirements of its environment. For example, TMEM16A is
thought to function as a calcium-dependent chloride channel (CaCC) with eight proposed
TM segments. Recent studies of the patterns of alternative splicing that produce distinct
isoforms of this protein show that differential exclusion/inclusion of exons 6b, 13, and 15 in
the mRNA transcript occurs in different organs (76). The liver, placenta, prostate, thyroid,
and trachea tend toward inclusion of exon 6b and exclusion of exon 15. However, in the
brain the mRNA is most often missing exon 6b but contains exon 15. Exon 13 skipping was
only found to occur only in brain and skeletal muscle. These changes in mRNA structure are
reflected in the protein structure with functional consequences. For instance, skipping of
exon 6b results in a deletion of a 22-amino acid intracellular segment in the N-terminus of
TMEM16A, leading to a much higher affinity of TMEM16A for intracellular Ca2+ ions.
Deletion of exon 13 results in removal of four amino acids in the intracellular loop between
TM segments 2 and 3, reducing the voltage-dependence of the Cl− currents.
AS can also involve non-coding regions of the mRNA. For instance, peripheral myelin
protein 22 (PMP22), a protein involved in the inherited peripheral neuropathy Charcot-
Marie-Tooth Disease, is spliced in a tissue-specific manner. The first exon in the 5'
untranslated region (UTR) is alternatively spliced to include exon 1a or exon 1b (77). Exon
1a dominates in myelinating Schwann cells, while exon 1b is common to non-neural tissues
expressing PMP22. Evidence suggests that expression of these two alternative transcripts is
actually regulated by two different upstream promoters in the DNA, with the resultant pre-
mRNA containing either exon 1a or 1b. The resultant proteins are identical, and it appears
that the different promoters and the different 5' exons act to differentially regulate PMP22
expression in a tissue-specific manner at both transcriptional and translational stages.
Impact of AS on Trafficking and Subcellular Distribution
Trafficking sequence motifs play key roles in directing the trafficking and subcellular
distribution of proteins within the cell. AS can result in the removal or retention of these
signals to directly affect protein trafficking and organelle sub-localization. For instance,
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there are two sets of N-ethylmaleimide- sensitive factor attachment protein (SNAP)
receptors (SNAREs). v-SNAREs are single-pass MPs embedded in the membranes of
vesicles, while t-SNAREs are embedded in the membranes of the target organelle. Together
these SNAREs work to fuse vesicles to their target destination, releasing the vesicular
contents. Importantly, there are two isoforms of the well-characterized v-SNARE vesicle-
associated MP-1 (VAMP-1), VAMP-1A and VAMP-1B, that differ in the sequence at their
C-termini, presumably through use of an alternative 3' exon. The VAMP-1B isoform is
targeted to the mitochondria via conferral of a positive charge to the C-terminus and
shortening of the hydrophobic membrane-embedded portion of the protein by four amino
acid residues, while the VAMP-1A isoform is localized to the plasma membrane and the
endosomes (78). Consequently, AS affects not only the trafficking of these important
proteins, but also likely affects the destination of the vesicular contents of VAMP-directed
vesicles (to the mitochondrial matrix for VAMP-1B and to extracellular matrix for
VAMP-1A). In another example, the lysosome-associated MP (LAMP) 2, a major
component of the lysosomal membrane, has three splice variants (LAMP-2a, -2b, and -2c)
that are trafficked either to lysosomal compartments (LAMP2c) or to the cell surface
(LAMP-2a and -2b). These differences are dictated by variation of their C-terminal targeting
sequence (79), which is governed by alternative splicing of the last exon in the transcript,
presumably through a mutually exclusive splicing event of the 3' exon.
Impact of AS on Folding
MP folding is still poorly understood in comparison to soluble protein folding and the
evidence for the impact of alternative splicing on MP stability, folding pathways, and
interactions with chaperones is currently sparse. Some AS events do result in the retention of
specific variants (but not others) in the ER, which may indicate that AS sometimes results in
changes in protein structure that are perceived by the protein folding quality control as
signatures of misfolding. For instance, the V2b variant of the vasopressin receptor (50) is
retained in the ER, as are two alterative isoforms of the TM aspartyl protease β-site APP
cleavage enzyme 1 (BACE1), BACE1 I-476 and I-457, which are also far less active than
the canonical BACE1 isoform I-501, (80). It has also been specifically suggested that V2b
might represent a destabilized form of the V2 vasopressin repressor (50), which is not
surprising considering that the V2b isoform has an altered topology (see Figure 3). To what
extent these apparent AS-encoded “misfolding” events are important for normal cell biology
(and are therefore evolutionarily selected for) remains to be seen. In any case, as the
technology for examining MP folding and misfolding becomes more accessible, care should
be taken to investigate the possible impact of AS on MP trafficking and folding efficiency.
AS of MPs and Disease
Alternative splicing of soluble proteins has long been documented as a contributing factor to
disease (43–46). Here, we review two disorders in which aberrant RNA splicing has a
pathological impact on MPs.
Myotonic Dystrophy Type 1
Myotonic Dystrophy Type 1 (DM1) is an inherited multisystem progressive disorder
affecting 1 in 8000 people. DM1 is characterized by myotonia, heart defects, cataracts,
gastrointestinal defects, insulin resistance, muscle wasting, and neuropsychiatric disorders
(81, 82). DM1 appears to be triggered by expansion of a CUG repeat in the 3' untranslated
region (3'-UTR) of the mytonic dystrophy protein kinase (DMPK) gene transcript (82). The
number of CUG repeats correlates with disease severity (83). The CUG-expanded RNA
accumulates in nuclear foci (84) and likely has a toxic gain of function mediated by
hyperphosphorylation. This leads to stabilization of CUG-repeat binding proteins, such as
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CUG binding protein (CUG-BP) (85, 86), a member of the CELF family of splicing
regulators, and sequestration of muscleblind (MNBL) (84, 87). Sequestration of MNBL and
stabilization of CUG-BP aberrantly alters AS of their downstream target transcripts (see
Figure 5). As such, DM1 can be classified as an indirect spliceopathy since, while no splice
sites are altered, AS of multiple proteins is dysregulated. While both soluble and MPs are
adversely affected, below we review the AS of MPs affected in this disease.
Insulin Receptor—Aberrant AS of the insulin receptor (InsR) results in the insulin
resistance phenotype observed in DM1 patients. The insulin receptor functions as a
heterotetramer with two α- and two β-subunits. In DM1, there is a switch from the normal
production in skeletal muscle of the IR-B splice variant of the α subunit, which includes a
12 residue C-terminus, to production of the IR-A variant lacking this terminus (88, 89).
Omission of the C-terminus results in reduced responsiveness of the InsR to insulin and
reduced kinase activity (and hence, signaling) for the IR-A isoform that is expressed in DM1
(90, 91).
Muscle-Specific Chloride Channel—One of the most common symptoms of DM-1 is
myotonia, a delay in the relaxation of muscle after contraction. Hyperexcitability is likely
caused by loss of function of chloride channels. It is thought that this is due to aberrant
alternative splicing of the muscle-specific chloride channel (ClC-1), which results in
decreased levels of the channel (92). Three aberrant splice variants of ClC-1 were found in
the skeletal muscle of DM-1 patients. All three of these disease-generated isoforms contain
premature stop codons introduced by the splicing changes and the transcripts are likely
degraded by nonsense-mediated decay. This results in the loss of functional translated ClC-1
in skeletal muscle and thus a decrease in chloride conductance across the membrane,
causing myotonia (93).
Ryanodine Receptor and Sarcoplasmic Endoplasmic Reticulum Ca2+ ATPase
—Perhaps the most debilitating symptom of DM-1 is muscle wasting and weakness. It has
been shown in other disorders that this symptom can result from changes to calcium
homeostasis in muscle cells that increase intracellular Ca2+ levels (94). Two proteins
essential to maintaining calcium homeostasis are the ryanodine receptor (RyR1) and the
sarcoplasmic endoplasmic reticulum Ca2+ ATPase (SERCA). The RyR1 is responsible for
the release of Ca2+ in storage in the sarcoplasmic reticulum during muscle contraction and
SERCA transports Ca2+ back across the ER membrane for storage. Research has shown that
the transcripts for both of these proteins undergo AS in DM-1 patients (95).
RyR1 has 2 variants seen in DM1: the neonatal form of RyR1 lacks exon 70 (residues 3481–
3485), which corresponds to five residues found in the receptor modulatory region, (96) and
the adult form RyR1 includes exon 70. Adult DM-1 patients have been found to have
elevated levels of the neonatal RyR1 isoform in their skeletal muscle. This form of RyR1
has lower channel activity than the adult isoform, which would result in increased
depolarization-dependent Ca2+ release (95).
Two SERCA genes, SERCA1 and SERCA2 are also implicated in DM-1. SERCA1 has two
splice variants: SERCA1a is the adult version of the protein and contains exon 22, which
encodes 7 amino acids at the C-terminus. The neonatal form, SERCA1b lacks exon 22, and
its C-terminus has an eight-residue, highly-charged C-terminal tail. In DM-1, a switch
occurs, where the major isoform produced is the neonatal form (SERCA1b) as opposed to
the adult form. It was also found that SERCA2 has a novel variant (SERCA2d) with lowered
expression in DM-1. SERCA2d contains intron 19, which results in the addition of 27 amino
acids, a frameshift, and a premature stop codon in exon 20. The aberrantly expressed
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SERCA isoforms both have an altered C-terminus, but how this impacts overall pump
function is not known (95).
Cav1.1 L-type Calcium Channel—The voltage-dependent Cav1.1 calcium channel plays
a central and important role in excitation/contraction coupling in skeletal muscle (97). This
channel also undergoes aberrant splicing that is associated with DM-1. AS of Cav1.1 in DM
patients results in omission of exon 29 (ΔE29), removing a portion of the extracellular loop
near the voltage sensor. As a consequence, the ΔE29 isoform exhibits altered calcium
channel gating, which increases Ca2+ influx. These defects result in Ca2+ overload, likely
contributing to muscle weakness and wasting.
Alzheimer’s Disease
Alzheimer’s Disease (AlzD) is a progressive neurodegenerative disorder affecting over 5
million people in the United States alone (98, 99). AlzD can arise sporadically or, in rare
cases, can be directly inherited (familial AlzD). While the etiology of the disease remains
the subject of intense scrutiny, the amyloidogenic pathway appears to play a central role
(100). Amyloid plaques containing the amyloid-β (Aβ) peptide build up in the brains of
AlzD patients and are the histological hallmark of the disease. It is thought, however, that it
is soluble Aβ oligomers or aggregates that confer neurotoxicity and are at least partially
responsible for AlzD progression (101). Aβ production occurs through the successive
release of the ectodomain of the amyloid precursor protein (APP) by β-secretase followed
by γ-secretase cleavage of the remaining 99-residue TM C-terminus to release the Aβ
peptides. In a competing (and benign) pathway of APP processing initiated by α-secretase, a
non-amyloidogenic peptide known as p3 is generated (102). The β- and γ-secretase
enzymes are TM proteins, with the β-secretase being the aspartyl protease BACE1 (103–
106). The γ-secretase complex is composed of four TM subunits: presenilin, nicastrin,
APH-1, and presenilin enhancer 2 (PEN2) (107). As discussed below, the β-secretase and
components of the γ-secretase complex are subject to AS, and this AS may regulate their
activities (see Figure 6). Additionally, there is evidence for the involvement of aberrant AS
in the progression of AlzD. Finally, APP is itself affected by AS. Here we review instances
of AS of MPs in AlzD and discuss the potential impact on disease progression and
therapeutics.
Amyloid Precursor Protein—Three major splice isoforms of APP have been
documented: APP695 (lacking exons 7 and 8; the predominant neuronal isoform), APP751
(lacking exon 8 and expressed abundantly in non-neuronal CNS tissue and peripheral
tissue), and APP770 (containing both exons 7 and 8 and expressed predominantly in
peripheral tissues and at only low levels in the CNS) (108, 109). Exon 7 encodes a Kunitz
protease inhibitor (KPI) domain in the ectodomain of APP that is possibly involved in
blocking the α-secretase-initiated non-amyloidogenic APP processing pathway, since
inclusion of exon 7 promotes production of Aβ and a decreased production of the p3 peptide
(110). However, it should be noted that this domain is a serine-protease inhibitor domain, so
would be unlikely to block the metalloproteinase α-secretase directly. Exon 8 encodes a
region of the protein between the KPI domain and a heparin-binding domain. All three APP
variants are subject to proteolytic processing along the amyloidogenic and non-
amyloidogenic pathways described above. There is much inconsistency in the literature
regarding differential expression of these isoforms in non-AlzD versus AlzD brains.
Because it is difficult to compare relative values obtained from relative quantification-PCR
among different studies, definitive in vivo data showing that differential AS of APP
predisposes a patient to AlzD is still lacking.
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BACE1—BACE1 is a single span MP with its catalytic subunit located in the ectoplasm.
BACE1 is a prominent target in the as-of-yet unsuccessful search for a drug to lower
amyloid-β production. A recent series of publications (111–114) has described the various
isoforms of BACE1 produced through AS. The longest isoform, I-501 (named for the
number of amino acids), is both the most active and most commonly produced. However,
AS events can also generate a series of shorter isoforms, including I-476, I-455, I-432, and
I-127. The I-127 mRNA transcript contains a premature stop codon and is degraded by
NMD; in addition, the small amount of translated I-127 protein isoform is subject to
degradation by the proteasome (113). The BACE1 I-476, I-457, I-455, and I-432 all exhibit
dramatically reduced activity relative to I-501, such that promotion of AS to generate the
shorter isoforms results in decreased Aβ secretion (114). Accordingly, promotion of AS of
the BACE1 pre-mRNA may be a viable therapeutic strategy for reducing Aβ production.
Recent experiments in the laboratory of Michael Wolfe have shown that I-501 production is
activated through the binding of heterogeneous nuclear ribonucleoprotein H (hnRNP H) to a
G-rich element in the third exon of BACE1 pre-mRNA (115). Because the 5' splice site
responsible for I-501 production is thought to be weaker than the upstream 5' splice site
(115) leading to the I-457 and I-453 isoforms, targeting the activation of I-501 production by
hnRNP H is a reasonable therapeutic strategy in the search for a way to reduce BACE1
activity, in this case by reducing production of the most active isoform of the enzyme.
Presenilin (PS)—PS is the aspartyl protease in the heterotetrameric γ-secretase complex
responsible for intramembrane cleavage of a large number of different single span MP
substrates (116–118), including the 99-residue TM C-terminus (C99) of the APP that is
released by BACE1 cleavage. Cleavage of C99 by γ-secretase releases the Aβ peptides (see
Figure 6A). After assembly into the γ-secretase, cleavage of auto-inhibited presenilin within
the intracellular loop located between TM segments 6 and 7 generates active γ-secretase.
The now active presenilin is comprised of a heterodimer of its N-terminal fragment (NTF)
and a loop-containing C-terminal fragment (CTF). The NTF and CTF each contribute an
aspartic acid residue necessary for catalysis (102, 119–121). Prior to its cleavage, the loop
that is clipped to generate active presenilin is thought to extend into the active site to block
catalysis.
Inherited mutations of presenilin-1 or presenilin-2 (PS-1 and PS-2) are one of the known
causes of familial (early onset) AlzD. Some of these mutations appear to impact pre-mRNA
splicing. Additionally, aberrant splicing of the presenilin transcript has been shown to occur
in the more common sporadic AlzD.
Presenilin-1—It has been shown that presenilin-1 (PS1) is affected by multiple splicing
events, and that some heritable PS-1 mutations modulate splicing. Here, we will discuss
three instances where splicing may play a role in disease progression.
First, in human tissues, two isoforms of PS1 are expressed that differ only by the inclusion
or exclusion of four amino acids, VRSQ, in the N-terminal domain (122). The VRSQ motif,
which is conserved among humans, rats, and mice, provides a putative phosphorylation
consensus site for protein kinase C (PKC) at a downstream threonine (122). This
phosphorylation event may play a role in regulating the trafficking of PS1. There is a
relative decrease of the longer isoform in some cases of sporadic (123) and familial AlzD
(124), suggesting a link between altered trafficking of PS1 and AlzD etiology.
Aberrant splicing of PS1 can also be induced by mutation. For instance, a mutation within
intron 4 was identified in several patients with early-onset AlzD (125, 126), which results in
production of three aberrant species of PS1. Two of these contain full or partial deletions of
exon 4 and result in truncation of the protein product; the third encodes insertion of a single
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threonine residue between the canonical residues 113 and 114 (126). Only the threonine-
insertion species was detected in brain homogenates, suggesting the AlzD phenotype most
likely results from the insertion species. This is supported by observation that transfection of
the Thr-insertion form of the enzyme into HEK-293 cells resulted in increased Aβ42
secretion (126).
Another interesting aberrant splicing event occurs when a mutation destroys a splice
acceptor site at exon 9 (127). This causes the deletion of exon 9, which encodes part of the
autoinhibitory loop including the site of activating cleavage of presenilin within the auto-
inhibitory loop (128). Because disruption of this loop is required to activate presenilin
activity (128, 129) and the elimination of the autocleavage site results in constitutively
active presenilin (116), it was originally thought that its elimination via AS is solely
responsible for the associated AlzD phenotype. However, it was later demonstrated that the
single point mutation (S290C) that also results from this splicing event may contribute to
AlzD pathogenesis by promoting increased Aβ42 production (Figure 6B) (130).
Presenilin-2—For presenilin-2 (PS2), an aberrant splicing event in sporadic AlzD,
resulting in exon 5 skipping (PS2V) and protein truncation, has been extensively
characterized (131–135). The removal of exon 5 causes a frameshift in exon 6 and
introduces a premature stop codon. The resulting PS2V mRNA encodes only the amino
terminus containing one predicted TM segment and an additional five C-terminal residues
(131, 132). The PS2V protein is found in the hippocampus and cerebral cortex of patients
with sporadic AlzD, accumulates in inclusion bodies that impair the unfolded protein
response, and results in increased Aβ production through an undefined mechanism (132). It
is possible that it may exert its effect through associations with other γ-secretase proteins or
through disruption of the unfolded protein response, preventing disposal of Aβ.
Recently, a novel splice variant of PS2, termed PS2β, was described to be a γ-secretase
inhibitor (136). Its expression is therefore predicted to be beneficial in terms of reducing the
risk for AlzD. This splice variant encodes the entire NTF plus the autoinhibitory hydrophilic
loop domain that typically resides between TM segments 6 and 7. However, the exons
encoding the entire CTF are not included in this isoform, such that this splice variant is
catalytically inactive. PS2β was found to reduce the interaction between APH-1 and
nicastrin and to inhibit Aβ secretion (136). It seems then, that PS2β may inhibit γ-secretase
activity by preventing assembly of the holoenzyme. Perhaps this isoform may represent an
endogenous means of repressing γ-secretase activity (Figure 6B).
Anterior Pharynx Defective-1—Another γ-secretase subunit, anterior pharynx
defective-1 (APH-1) is a seven-TM spanning protein encoded by two homologous human
genes, either APH-1a or APH-1b (137). APH-1 is known to be responsible for assembly of
an initial subcomplex with nicastrin, and together these two proteins recruit the presenilin
and PEN2 (138–142). The APH-1a transcript can be alternatively spliced to produce one of
two isoforms, APH-1aS and APH-1aL, which differ only at their C-termini (137). These
splice variants have been shown to reside in distinct, active γ-secretase complexes (143).
Additionally, a novel (third) splice variant, APH-1bΔ4, has been identified that lacks the
entire fourth exon, meaning it also lacks the entire fourth TM segment (144), resulting in
predicted inversion of topology for the three C-terminal TM segments. This omitted TM
segment also contains a GXXXG motif that is thought to be critical for assembly of the γ-
secretase multisubunit complex (145) (Figure 6C). Endogenous expression of this variant
form of the protein is very low, and the protein is destabilized (144). Whether alternative or
aberrant splicing of APH-1 plays any role in promoting or preventing AlzD has yet to be
determined.
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Nicastrin—Nicastrin is a highly glycosylated type I MP that participates, along with
APH-1, in the assembly of the γ-secretase complex. Two independent genome surveys (146,
147) have found evidence for association of sporadic AlzD with the region of chromosome 1
on which the nicastrin gene resides.
In 2005, a novel skipped splice variant of nicastrin was reported to be expressed in rat
tissues and a human neuroblastoma cell line (148). This variant, which encodes a truncated
62-residue protein due to exon 3 removal resulting in a premature stop-codon, was shown to
be preferentially made in the central nervous system and is subject to degradation by NMD.
It is possible that NMD plays a specific role in the healthy CNS to down-regulate expression
of active γ-secretase, thereby reducing Aβ production.
Soon thereafter, a second novel nicastrin splice variant was identified, this time lacking the
entirety of exon 16 (149). As a result, this splice variant is missing 71 residues preceding the
N-terminal region of the TM domain, which was shown to be required for interaction with
the γ-secretase complex (150).
5-HT4 Receptor—The serotonin (5-hydroxytryptamine) receptor 5-HT4, a GPCR, has
been implicated in the regulation of APP processing and receptor agonists have been shown
to increase the production of the soluble APP ectodomain released by α-secretase cleavage
of full length APP to initiate the non-amyloidogenic pathway (151–153). Alternatively
spliced isoforms of 5-HT4 have intracellular C-terminal domains of different lengths: a short
isoform, 5-HT4(d), which contains only two amino acids after the C-terminal splice site,
located after the region encoding TM segment 7 and preceding the intracellular C-terminal
tail, and a larger isoform that contains 20 amino acids after the C-terminal splice site, 5-HT4.
These isoforms were compared with respect to the promotion of non-amyloidogenic APP
processing (154). It was found that not only does activation of the short 5-HT4(d) isoform by
agonist promote generation of non-amyloidogenic soluble-APPα (sAPPα, the ectodomain
released upon α-secretase cleavage), but also that, unlike the longer isoform, stimulation of
the short isoform reduces Aβ production. It is possible then, that 5-HT4 receptor isoforms
may differentially regulate APP processing. Presumably, this may come from signal
transduction differences related to the differing C-terminal tail lengths, possibly involving
signaling through arrestins, which become activated when they bind to the multiply-
phosphorylated C-termini of activated GPCRs. Such arrestin-based signaling would be
eliminated in splice variants that removed all or key parts of the C-terminal domain of the 5-
HT4 receptor. Further insight into how 5-HT4 receptors influence APP processing and their
relationship with the secretases is needed to shed light on this data.
Concluding Remarks
Alternative splicing of pre-mRNA can impact membrane protein trafficking, structure,
function, and ultimately, contribute to disease. The examples highlighted in this review
represent only a sample from what is already a very large pool of literature on this subject.
Given that studies of RNA splicing remain in a rapid state of development, these examples
represent only modest beginnings. There are undoubtedly new discoveries waiting to be
made. It is already clear that splicing can alter almost every aspect of a MP’s structure,
topology, function, trafficking, and interactions. When studying MPs from eukaryotes, the
possibility of different isoforms with varying properties should not be overlooked.
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Figure 1. Modes of AS
(A) Exon skipping. Top: canonical splicing. Bottom: removal of the blue exon. (B)
Alternative donor sites. Top: canonical splicing. Bottom: use of an alternative 5' donor site.
(C) Alternative acceptor sites. Top: canonical splicing. Bottom: use of an alternative 3'
acceptor site. (D) Intron retention. In cases of intron retention, the canonical splicing (dotted
line) does not occur and the intron is included in the processed mRNA. (E) Mutually
exclusive exon splicing. Top: inclusion of blue exon and exclusion of red exon. Bottom:
exclusion of blue exon and inclusion of red exon.
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Figure 2. Spliceosome assembly and splicing reaction
From top, clockwise: U1 snRNP associates with the 5' splice site to make complex E. U2
snRNP is recruited and brings the branch site near the 5' splice site, forming complex A. The
U4/U6.U5 tri-snRNP is recruited to form a pre-catalytic complex B. The arrival of the
nineteen complex (NTC) and the release of U1 and U4 snRNAs mark the conversion to
complex B*, an active spliceosome. Complex C forms after the first transesterification
reaction and carries out the second transesterification reaction. The mature message is
released and the post-splicing complex is recycled.
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Figure 3. AS can alter MP topology
(A) The membrane topology of the RhCcEe protein is altered due to AS. RhX1b is the
canonical isoform; helices are numbered per this isoform. Exon removal in RhVIII results in
the removal of TM segments 6–10. The original TM segments 11–13 (purple) cross the
membrane with inverted topology. RhVI, as a result of exon removal, is missing the residues
that form TM segments 6–8 and also displays inverted topology in the canonical TM
segments 9–11. Additionally, RhVI has another deletion due to exon removal. This deletion
causes a frameshift and results in a different C-terminal sequence with a premature stop
codon. The Rh4 isoform undergoes exon removal that induces a frameshift resulting in a
different C-terminal sequence and a premature stop codon at the same location as in RhVI.
The new C-terminal sequence generated by the frameshift in RhVI and Rh4 encodes the
same 14 amino acids (orange), indicating that the sequence likely is important. (B) The G-
protein coupled receptor V2 vasopressin receptor. V2a is a stably expressed seven-TM
segment (7-TM) protein found at the plasma membrane. Conversely, V2b differs in
sequence from V2a in the C-terminal region after the sixth TM segment. This alteration in
the C-terminus results from the use of an alternate 3' splice site 76 base pairs downstream of
the canonical 3' splice site, which causes a frameshift. The V2b protein isoform was
experimentally shown to significantly populate two topologies: a 7-TM topology similar to
canonical GPCRs with the C-terminus located intracellularly, and a 6-TM topology with the
C-terminus oriented to the extracellular matrix. (C) The glycine receptor β subunit is
alternatively spliced to remove exon 7 (βΔ7). The long isoform of the β subunit including
exon 7 possesses has four-TM topology. The βΔ7 variant has a predicted two-TM segment
topology due to the removal of the tenth β-strand in the extracellular domain, TM segment
1, the first intracellular loop, and a portion of TM segment 2 (grey). The remaining portion
of TM segment 2 is predicted to substitute for the tenth β strand in the extracellular domain
(orange).
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Figure 4. AS can alter MP function
(A) AS of syndecan-4 results in an mRNA that encodes only the ectodomain. This AS event
may serve a similar purpose as proteolytic shedding of ectodomains. (B) AS of TRPM8
creates a short isoform (red) that regulates TRPM8 through interaction with the C-terminal
domain, acting to stabilize the closed formation of the channel. (C) AS of GLT1 results in
isoforms with different C-terminal tails. GLT1b and GLT1c contain different C-terminal
sequences (orange), but both include a PDZ-binding motif (black) that presumably functions
to recruit proteins that contain PDZ-domains. GLT1a does not possess this motif. (D) AS of
CA XII results in the removal of a GXXXG motif (red) that mediates dimerization. This
may prevent homodimerization and influence the activity of the enzyme. (E) AS hCB1
results in different N-termini (orange) and altered receptor responses to canonical ligands,
presumably through an allosteric effect. (F) Alternative splicing of PLP results in removal of
a portion of a loop that includes sites for post-translational lipid modifications. Removal of
these sites may influence protein trafficking to lipid raft domains.
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Figure 5. CUG repeats in DMPK gene cause dysregulation of AS
Mutation of the DMPK gene to include CUG repeats sequesters the MNBL1 protein and
stimulates hyperphosphorylation of the CUG-BP through a PKC-mediated mechanism.
These changes result in dysregulated splicing of downstream targets of MNBL1 and CUG-
BP.
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Figure 6. AS affects multiple proteins in the amyloidogenic pathway of AlzD
(A) APP processing pathways. Left: Non-amyloidogenic processing is initiated by α-
secretase to produce C83, which is further processed by γ-secretase to produce the amyloid
precursor protein intracellular domain (AICD) and the p3 peptide. Right: amyloidogenic
processing is initiated by β-secretase to produce C99, which is further processed by γ-
secretase to produce the AICD and the Aβ peptide. The Aβ peptide can form toxic
oligomers and aggregates. Proteins affected by AS are highlighted in blue. (B) Alternative
splicing of presenilin impacts γ-secretase activity. Exon 9 removal in PS1 results in a
constitutively active form of the protein by considerably shortening the autoinhibitory loop
and removing the endoproteolytic cleavage site. Exon 5 skipping in PS2 results in protein
truncation after the autoinhibitory loop, creating a variant that is missing the CTF that is
required for catalytic activity. (C) Exon 4 removal in APH-1b results in removal of the
entire fourth TM segment, causing inverted topology of the last three TM segments (purple).
This also results in the omission of the GXXXG motif that is required for γ-secretase
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assembly. (D) AS of the 5-HT4 receptor results in a much shorter C-terminal tail, which
presumably alters the signaling properties of this GPCR.
Mittendorf et al. Page 31
Biochemistry. Author manuscript; available in PMC 2013 July 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
